The Brand Name QUGYL Has Generic Salt :: Metronidazole
QUGYL Is From Company Rpg Life Priced :: Rs. 7.9
QUGYL have Metronidazole is comes under Sub class #N/A of Main Class #N/A
Main Medicine Class:: #N/A Sub Medicine Class :: #N/A
|Salt Name : OR Generic Name||Form||Price : MRP /Probable||Packing|
|Metronidazole||DS TAB||Rs. 7.9||3|
Indications for Drugs ::
Pneumonia, Giardiasis, Peptic ulcer disease, Peritonitis, H. pylori infection, Rosacea, Septicemia, Endometritis, Aspiration pneumonia, Lung abscess, Empyema, Bone and Joint Infections, Surgical Prophylaxis, Amoebiasis, Bacterial vaginosis, Balantidiasis, Blastocystis hominis infection, Trichomoniasis, Acute dental infections, Acute necrotising ulcerative gingivitis, Anaerobic bacterial infections, Antibiotic-associated colitis, Fungating tumours, Leg ulcers and pressure sores, Diverticulitis, Diabetic foot ulcer, Meningitis and brain abscesses, endocarditis
Drug Dose ::
Adults & Children (over 10 years): PO Amoebiasis; Balantidiasis; Blastocystis hominis infection 400-800 mg 3 times/day for 5-10 days. Trichomoniasis 2 g as a single dose for 2 days or 0.6-1 g/day in 2-3 divided doses for 7 days. Repeat 4-6 wk later if needed. Giardiasis 2 g once daily for 3 consecutive days. Acute dental infections; Acute necrotising ulcerative gingivitis 200 mg 3 times/day. Anaerobic bacterial infections Initial: 800 mg, then 400 mg 8 hrly for about 7 days. Surgical prophylaxis 400 mg 8 hrly in the 24 hr before surgery followed post-op by IV or rectal route until PO is possible. Eradication of H. pylori associated w/ peptic ulcer disease W/ omeprazole and amoxicillin: 400 mg 3 times/day for 1 wk. Leg ulcers and pressure sores 400 mg 3 times/day for 7 days. Antibiotic-associated colitis 250-500 mg 2-3 times/day for 10-14 days. Change to oral vancomycin if no clear response after 2 days. IV: Anaerobic bacterial infections 500 mg 8 hrly. Surgical prophylaxis 500 mg shortly pre-op and repeat 8 hrly. Substitute w/ oral doses at 200 or 400 mg 8 hrly as soon as possible. Children: IV: 7.5 mg/kg (1.5 ml/kg) 8 hourly.
History of hypersensitivity to metronidazole or other nitroimidazole derivatives. Pregnancy (1st trimester) and lactation.
Drug Precautions ::
Patients with CNS diseases; discontinue IV therapy if abnormal neurologic symptoms occur. History of seizure disorder. Evidence or a history of blood dyscrasias; perform total and differential leukocyte counts before and after treatment. Severe hepatic impairment; monitor plasma levels. Predisposition to oedema (inj contains sodium). Prolonged use may result in fungal or bacterial superinfection.
Drug Side Effects ::
GI disturbances e.g. nausea, unpleasant metallic taste, vomiting, diarrhoea or constipation. Furred tongue, glossitis, and stomatitis due to overgrowth of Candida. Rarely, antibiotic-associated colitis. Weakness, dizziness, ataxia, headache, drowsiness, insomnia, changes in mood or mental state. Numbness or tingling in the extremities, epileptiform seizures (high doses or prolonged treatment). Transient leucopenia and thrombocytopenia. Hypersensitivity reactions. Urethral discomfort and darkening of urine. Raised liver enzyme values, cholestatic hepatitis, jaundice. Thrombophlebitis (IV). Potentially Fatal: Anaphylaxis.
Pregnancy category ::
Drug Mode of Action ::
Metronidazole is converted to reduction products that interact w/ DNA to cause destruction of helical DNA structure and strand leading to a protein synthesis inhibition and cell death in susceptible organisms. It is active against most anaerobic protozoa, some gm+ve, gm-ve and facultative anaerobes.
Drug Interactions ::
Concurrent use w/ disulfiram may produce psychotic reactions. May potentiate the effect of oral anticoagulants. May increase risk of lithium toxicity. May reduce the renal clearance resulting to increased toxicity of 5-fluorouracil. May increase serum levels of ciclosporin. May increase plasma levels of busulfan resulting to severe busulfan toxicity. Enhanced metabolism w/ phenobarbital and phenytoin resulting to decreased serum concentrations.